We are live on ! Find out more
APLT

Applied Therapeutics

Delisted

APLT was delisted on the 2nd of February, 2026.

90 hedge funds and large institutions have $51.8M invested in Applied Therapeutics in 2025 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 27 increasing their positions, 32 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more call options, than puts

Call options by funds: $226K | Put options by funds: $97K

7.75% less ownership

Funds ownership: 98.89%91.14% (-7.8%)

16% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 32

24% less funds holding

Funds holding: 11990 (-29)

47% less capital invested

Capital invested by funds: $98.5M → $51.8M (-$46.7M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

73% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 40

Holders
90
Holders Change
-29
Holders Change %
-24.37%
% of All Funds
1.21%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
11
Increased
27
Reduced
32
Closed
40
Calls
$226K
Puts
$97K
Net Calls
+$129K
Net Calls Change
-$323K
Name Holding Trade Value Shares
Change
Change in
Stake
VPC
1
Vestal Point Capital
New York
$5.62M
PBM
2
Propel Bio Management
California
$5.52M +$983K +1,670,000 +17%
T. Rowe Price Investment Management
3
T. Rowe Price Investment Management
Maryland
$5.08M +$2.92M +4,959,670 +91%
BlackRock
4
BlackRock
New York
$4.67M +$150K +255,227 +3%
KCM
5
Knoll Capital Management
Florida
$3.81M +$1.18M +2,000,000 +34%
Vanguard Group
6
Vanguard Group
Pennsylvania
$2.88M +$201K +340,962 +6%
VA
7
VR Adviser
New York
$2.72M -$2.6M -4,422,882 -44%
SSA
8
Schonfeld Strategic Advisors
New York
$2.28M -$2.41M -4,088,678 -47%
SAM
9
Simplify Asset Management
Nevada
$2.19M +$983K +1,670,000 +59%
Deutsche Bank
10
Deutsche Bank
Germany
$2.19M -$905 -1,537 -0%
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$1.52M +$236K +400,000 +15%
Morgan Stanley
12
Morgan Stanley
New York
$1.4M -$3.5M -5,943,556 -67%
TCM
13
Tang Capital Management
California
$1.19M
Geode Capital Management
14
Geode Capital Management
Massachusetts
$1.05M +$39.6K +67,250 +3%
RSCM
15
Rock Springs Capital Management
Maryland
$1.01M +$92.9K +157,700 +8%
Franklin Resources
16
Franklin Resources
California
$979K -$37 -62 -0%
Adage Capital Partners
17
Adage Capital Partners
Massachusetts
$959K
State Street
18
State Street
Massachusetts
$954K -$68K -115,427 -6%
Qube Research & Technologies (QRT)
19
Qube Research & Technologies (QRT)
United Kingdom
$948K -$6.78K -11,517 -0.6%
Marshall Wace
20
Marshall Wace
United Kingdom
$641K
Two Sigma Investments
21
Two Sigma Investments
New York
$470K +$393K +666,777 +227%
PA
22
Perceptive Advisors
New York
$420K
Northern Trust
23
Northern Trust
Illinois
$376K -$3.6K -6,113 -0.8%
Two Sigma Advisers
24
Two Sigma Advisers
New York
$322K +$388K +658,400 New
Charles Schwab
25
Charles Schwab
California
$309K -$40.2K -68,307 -10%

APLT Hedge Fund Activity: Q1 2025 in Review

90 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q1 2025, worth a combined $51.8M — down 47% from $98.5M a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of APLT and 11 opened new positions — a net loss of 29 holders — while 32 trimmed existing stakes and 27 added.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $2.92M. The largest seller was Morgan Stanley, cutting an estimated $3.5M.

  • 90 institutional investors held Applied Therapeutics (APLT) as of Q1 2025, down from 119 in Q4 2024.
  • Funds reported $51.8M of Applied Therapeutics stock for Q1 2025, down 47% quarter-over-quarter.
  • 11 funds opened new Applied Therapeutics positions in Q1 2025 and 40 closed out, a net change of -29 holders.
  • The largest Applied Therapeutics buyer in Q1 2025 was T. Rowe Price Investment Management, an estimated $2.92M added.
  • The largest Applied Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $3.5M sold.

Based on aggregated 13F filings for Q1 2025.